(FILE 'HOME' ENTERED AT 17:24:35 ON 08 OCT 2000)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, CANCERLIT, SCISEARCH, TOXLINE, CAOLD, APIPAT, APIPAT2, CROPU, DGENE, DPCI, EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PCTFULL, PIRA, RAPRA, TULSA, TULSA2, USPATFULL, ...' ENTERED AT 17:24:54 ON 08 OCT 2000

L1 601654 S GLYCOPROTEIN OR CONJUGATE
L2 1364464 S MANNOSE OR GALACTOSE OR N-ACETLYGLUCOSAMINE OR N-ACETYLLACTOS
L3 14682 S L1 (30A) L2
L4 35854 S PRODRUG
L5 9 S L3 (30A) L4
L6 6 DUP REM L5 (3 DUPLICATES REMOVED)
L7 5979823 S TUMOR OR CANCER OR MALIGNAN#### OR TUMOUR OR NEOPLAS###
L8 557 S L7 (30A) L3
L9 2963340 S ENZYME OR ENZYMATIC
L10 52 S L8 (30A) L9
L11 31 DUP REM L10 (21 DUPLICATES REMOVED)
L12 2828955 S ANTIBOD### OR FUSION GLYCOPROTEIN OR CONJUGATE
L13 52 S L1 (30A) L2 (30A)L7 (30A) L9
L14 31 DUP REM L13 (21 DUPLICATES REMOVED)

L6 ANSWER 2 OF 6 USPATFULL
AN 1998:61623 USPATFULL
TI Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors
IN Rubin, David, San Diego, CA, United States
PA CO Enzyme Technology Ltd., San Diego, CA, United States (U.S. corporation)
PI US 5760008 19980602
AI US 1996-666643 19960618 (8)
RLI Continuation-in-part of Ser. No. US 1994-360352, filed on 21 Dec 1994, now patented, Pat. No. US 5639737 which is a continuation-in-part of Ser. No. US 1993-138195, filed on 20 Oct 1993, now patented, Pat. No. US
5476842 which is a continuation-in-part of Ser. No. US 1991-787347, filed on 4 Nov 1991, now abandoned And a continuation-in-part of Ser. No. US 1993-57666, filed on 5 May 1993, now patented, Pat. No. US 5340803
DT Utility
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Lee, Howard C.
LREP Browdy and Neimark
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1248
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . this specification, can be achieved by administering glucose to
the patient thirty minutes prior to the treatment, as orally administered **glucose** expresses itself in acidification of the tumor due to accumulation of lactic acid. Of course, if the **prodrug conjugate** used is a **glucose conjugate**, an acidification compound other than **glucose**

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	33286	glycoprotein or conjugate	USPAT	2000/10/08 17:15			0
2	BRS	L2	61701	mannose or galactose or N-acetylglucosamine or n-acetyllactose or glucose or fucose	USPAT	2000/10/08 17:16			0
3	BRS	L3	651	1 near30 2	USPAT	2000/10/08 17:17			0
4	BRS	L4	3191	prodrug	USPAT	2000/10/08 17:17			0
5	BRS	L5	3	3 near50 4	USPAT	2000/10/08 17:17			0
6	BRS	L6	51189	tumor or cancer or malignan$4 or tumour neoplas$3	USPAT	2000/10/08 17:18			0
7	BRS	L7	21	3 near50 6	USPAT	2000/10/08 17:18			0